Recombinant Therapeutic Proteins Market Sales Revenue Clinical Trials Pipeline Report

roteins are known to be the building blocks of life, and as a part of the natural metabolism, they are synthesized by all living forms. Some proteins, such as enzymes, tend to serve as biocatalysts, which help in increasing the rate of metabolic reactions. There are other types of proteins which form the cytoskeleton. There is a significant role played by proteins in functions like cell signaling, immune responses, cell adhesion, and the cell cycle. In industries, proteins are commercially produced by using genetic engineering and protein engineering. There are many sectors such as the biopharmaceutical industry, the enzyme industry, and the agricultural industry, which are significantly benefitted from native and recombinant proteins. In return the products manufactured in these industries tend to support the fields of medicine, diagnostics, food, nutrition, detergents, textiles, leather, paper, pulp, polymers and plastics.

Download Report:

https://www.kuickresearch.com/report-Recombinant-Therapeutic-Proteins-Market-&-Pipeline-Analysis.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Recombinant Therapeutic Proteins Market & Pipeline Analysis" Table of Contents

1. What Are Recombinant Proteins?
1.1 Recombinant Proteins Overview
1.2 History of Recombinant Proteins

2. Why There Exist Need for Recombinant Proteins?

3. Different Types of Recombinant DNA Technology

4. Mechanisms of Recombinant Protein Production
4.1 Recombinant Protein Production & Expression
4.2 Different Methods of Protein Production
4.3 Process for Producing Recombinant Proteins

5. Global Recombinant Therapeutic Proteins Market Overview
5.1 Current Market Scenario
5.2 Recombinant Proteins Clinical Pipeline Overview

6. Global Recombinant Therapeutic Proteins Market Dynamics
6.1 Market Drivers
6.2 Challenges

7. Recombinant Therapeutic Proteins Market Future Growth Outlook

8. Recombinant Therapeutic Proteins Clinical Pipeline by Phase, Indication, Company, & Country
8.1 Research till Registration
8.2 Marketed Recombinant Therapeutic Protein Drugs
8.3 Suspended & Discontinued Drugs in Clinical Pipeline

9. Recombinant Erythropoietins Clinical Pipeline by Phase, Indication, Company, & Country
9.1 Research till Registration
9.2 Marketed Recombinant Erythropoietin Drugs
9.3 Suspended & Discontinued Drugs in Clinical Pipeline

10. Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase, Indication, Company, & Country
10.1 Research till Registration
10.2 Marketed Recombinant Fusion Protein Drugs
10.3 Suspended & Discontinued Drugs in Clinical Pipeline

11. Competitive Landscape
11.1 Boehringer Ingelheim
11.2 Bristol-Myers Squibb
11.3 Celldex Therapeutics
11.4 Eli Liily
11.5 GlaxoSmithKline
11.6 Merck
11.7 Novartis
11.8 Regeneron Pharmaceuticals
11.9 Roche
11.10 Shire Pharmaceuticals

Figure 1-1: Most Commonly Used Recombinant Protein Products
Figure 1-2: Biopharmaceutical Approval in European Union & US During 2008-2013
Figure 3-1: Recombinant DNA Technologies
Figure 4-1: Process for Producing Recombinant Proteins
Figure 5-1: Global Biologics Market Classification

Figure 5-2: Global Protein Therapeutics Market (US$ Billion), 2013-2020
Figure 5-3: Global Therapeutic Protein Market by Region (%), 2014
Figure 5-4: Share of Producing Agents for Recombinant Proteins, 2014

Figure 5-5: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-6: Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-7: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-8: No Development Reported in Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-9: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-10: Discontinued Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-11: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-12: Suspended Recombinant Therapeutic Proteins Clinical Pipeline by Phase (Number), 2014

Figure 5-13: Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014
Figure 5-14: Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014
Figure 5-15: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (%), 2014
Figure 5-16: Discontinued Recombinant Erythropoietins Clinical Pipeline by Phase (Number), 2014

Figure 5-17: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-18: Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-19: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-20: No Development Reported in Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014
Figure 5-21: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (%), 2014
Figure 5-22: Discontinued Recombinant Therapeutic Fusion Proteins Clinical Pipeline by Phase (Number), 2014

List of Tables

Table 1-1: First Generation of Therapeutic Proteins
Table 1-2: Second Generation of Therapeutic Proteins
Table 1-3: Monoclonal Antibodies

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.